- Email: [email protected]
4869899 Pharmaceutical preparation and process for producing the same
New
Patents
vii
and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.
other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.
4868211
4868344
DERIVATIVES OF L-AMINO ACYL L-CARNITINE, PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS HAVING HEPATOPROTECTING ACTIVITY CONTAINING SAME
NOVEL PROCESS OF PRODUCING PHENYL OR SUBSTITUTED PHENYLALKYLAMINE PHARMACEUTICAL AGENTS AND NOVEL CHIRAL INTERMEDIATES OF HIGH ENANTIOMERIC PURITY USEFUL THEREIN
Maria O Tinti, Carlo A Bagolini, Domenic Misiti, Carlo Scolastico, Rome, Italy assigned to 501 Sigma Tau Industrie Farmaceutiche Riunite SpA L-aminoacyl derivatives of L-carnitine of general formula (I) See Patent for Chemical Structure (I) wherein R is an alkyl radical selected from Imethyl-propyl, isobutyl, isopropyl, mercaptomethyl and 3-guanidino propyl, and their pharmacologically acceptable salts, are prepared e.g. by reacting a solution in an organic solvent of L-carnitine whose carboxyl group is protected with an N-protected aminoacid in the presence of a condensing agent and then removing the amino-acid and carnitine protecting groups, thus obtaining the desired compound.
4868212 PHARMACEUTICAL AND DIETARY COMPOSITION David F Horrobin, Montreal, Canada assigned to Efamol Ltd A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of alpha-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or
Herbert C Brown assigned to Aldrich-Boranes Inc A process for producing the optically pure (+)or (-) isomer of a phenyl- or substitutedphenylalkanolamine compounds having pharmacologic activity without the need for resoltuion processes ad novel intermediates useful in the process including optically pure haloalcohols are provided.
4869899 PHARMACEUTICAL PREPARATION AND PROCESS FOR PRODUCING THE SAME Walter Burghart, Kurt Vienna, Austria
Burghart, A
1030
A pharmaceutical preparation contains an active ingredient added to polyaicohols, such as polyethylene and/or polyalkylene glycols and/or oxystearates of glycerine-polyethyleneglycol and/or partial fatty acid esters of sorbitan or polyhydroxyethylenesorbitan and/or polyvinylpyrrolidone and/or polyvinylaicohols and/or fatty alcohol ethers of polyhydroxyethylene or fatty acid ester of polyhydroxyethylene and/or condensates of polyhydroxyethylenepolyhydroxypropylene, and especially dissolved in nifedipine in a weight ratio between 1:2 and 1:25. The composition contains ethanol as well, in an amount ratio between 1:25 and 1:4 of nifedipine:ethanol and can be sprayed with a propeller gas.
Patents
vii
and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.
other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.
4868211
4868344
DERIVATIVES OF L-AMINO ACYL L-CARNITINE, PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS HAVING HEPATOPROTECTING ACTIVITY CONTAINING SAME
NOVEL PROCESS OF PRODUCING PHENYL OR SUBSTITUTED PHENYLALKYLAMINE PHARMACEUTICAL AGENTS AND NOVEL CHIRAL INTERMEDIATES OF HIGH ENANTIOMERIC PURITY USEFUL THEREIN
Maria O Tinti, Carlo A Bagolini, Domenic Misiti, Carlo Scolastico, Rome, Italy assigned to 501 Sigma Tau Industrie Farmaceutiche Riunite SpA L-aminoacyl derivatives of L-carnitine of general formula (I) See Patent for Chemical Structure (I) wherein R is an alkyl radical selected from Imethyl-propyl, isobutyl, isopropyl, mercaptomethyl and 3-guanidino propyl, and their pharmacologically acceptable salts, are prepared e.g. by reacting a solution in an organic solvent of L-carnitine whose carboxyl group is protected with an N-protected aminoacid in the presence of a condensing agent and then removing the amino-acid and carnitine protecting groups, thus obtaining the desired compound.
4868212 PHARMACEUTICAL AND DIETARY COMPOSITION David F Horrobin, Montreal, Canada assigned to Efamol Ltd A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of alpha-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or
Herbert C Brown assigned to Aldrich-Boranes Inc A process for producing the optically pure (+)or (-) isomer of a phenyl- or substitutedphenylalkanolamine compounds having pharmacologic activity without the need for resoltuion processes ad novel intermediates useful in the process including optically pure haloalcohols are provided.
4869899 PHARMACEUTICAL PREPARATION AND PROCESS FOR PRODUCING THE SAME Walter Burghart, Kurt Vienna, Austria
Burghart, A
1030
A pharmaceutical preparation contains an active ingredient added to polyaicohols, such as polyethylene and/or polyalkylene glycols and/or oxystearates of glycerine-polyethyleneglycol and/or partial fatty acid esters of sorbitan or polyhydroxyethylenesorbitan and/or polyvinylpyrrolidone and/or polyvinylaicohols and/or fatty alcohol ethers of polyhydroxyethylene or fatty acid ester of polyhydroxyethylene and/or condensates of polyhydroxyethylenepolyhydroxypropylene, and especially dissolved in nifedipine in a weight ratio between 1:2 and 1:25. The composition contains ethanol as well, in an amount ratio between 1:25 and 1:4 of nifedipine:ethanol and can be sprayed with a propeller gas.